Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Precigen, Inc.

Collaboration and Licensing Revenue

Collaboration and Licensing Revenue %Chg

Collaboration and Licensing Revenue Common Size

Product Revenues

Product Revenues %Chg

Product Revenues Common Size

Service Revenues

Service Revenues %Chg

Service Revenues Common Size

Other Revenues

Other Revenues %Chg

Other Revenues Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Products

Cost of Products %Chg

Cost of Products Common Size

Cost of Services

Cost of Services %Chg

Cost of Services Common Size

Cost of Products and Services

Cost of Products and Services %Chg

Cost of Products and Services Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

Selling, General and Administrative

Selling, General and Administrative %Chg

Selling, General and Administrative Common Size

Impairment of Goodwill

Impairment of Goodwill %Chg

Impairment of Goodwill Common Size

Impairment Loss

Impairment Loss %Chg

Impairment Loss Common Size

Impairment of Other Noncurrent Assets

Impairment of Other Noncurrent Assets %Chg

Impairment of Other Noncurrent Assets Common Size

Total Operating Expenses

Total Operating Expenses %Chg

Total Operating Expenses Common Size

Operating Loss

Operating Loss %Chg

Operating Loss Common Size

Unrealized and Realized Appreciation (Depreciation) in Fair Value of Equity Securities and Preferred Stock, Net

Unrealized and Realized Appreciation (Depreciation) in Fair Value of Equity Securities and Preferred Stock, Net %Chg

Unrealized and Realized Appreciation (Depreciation) in Fair Value of Equity Securities and Preferred Stock, Net Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Interest and Dividend Income

Interest and Dividend Income %Chg

Interest and Dividend Income Common Size

Other Income, Net

Other Income, Net %Chg

Other Income, Net Common Size

Total Other Income, Net

Total Other Income, Net %Chg

Total Other Income, Net Common Size

Equity in Net Loss of Affiliates

Equity in Net Loss of Affiliates %Chg

Equity in Net Loss of Affiliates Common Size

Equity in Net Income of Affiliates

Equity in Net Income of Affiliates %Chg

Equity in Net Income of Affiliates Common Size

Total Other Expense, Net

Total Other Expense, Net %Chg

Total Other Expense, Net Common Size

Loss from Continuing Operations Before Income Taxes

Loss from Continuing Operations Before Income Taxes %Chg

Loss from Continuing Operations Before Income Taxes Common Size

Income Tax Benefit

Income Tax Benefit %Chg

Income Tax Benefit Common Size

Loss from Continuing Operations

Loss from Continuing Operations %Chg

Loss from Continuing Operations Common Size

Loss from Discontinued Operations, Net of Income Tax Benefit

Loss from Discontinued Operations, Net of Income Tax Benefit %Chg

Loss from Discontinued Operations, Net of Income Tax Benefit Common Size

Income from Discontinued Operations, Net of Income Tax Benefit

Income from Discontinued Operations, Net of Income Tax Benefit %Chg

Income from Discontinued Operations, Net of Income Tax Benefit Common Size

Net Loss

Net Loss %Chg

Net Loss Common Size

Net Loss Attributable to the Noncontrolling Interests

Net Loss Attributable to the Noncontrolling Interests %Chg

Net Loss Attributable to the Noncontrolling Interests Common Size

Net Loss Attributable to Precigen

Net Loss Attributable to Precigen %Chg

Net Loss Attributable to Precigen Common Size

From Continuing Operations Attributable to Precigen

From Continuing Operations Attributable to Precigen %Chg

From Continuing Operations Attributable to Precigen Common Size

From Discontinued Operations Attributable to Precigen

From Discontinued Operations Attributable to Precigen %Chg

From Discontinued Operations Attributable to Precigen Common Size

Net Income from Discontinued Operations Attributable to Precigen

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	6.3	4.3	4.2	3.9	4	4.4
Total Revenues %Chg	59.2%	-1.1%	-22.8%	-36.9%	-41.4%	-80.1%
Product Revenues
Service Revenues
Other Revenues
Collaboration and Licensing Revenue
Cost of Sales	4.4	4.4	4.3	4.3	4.5	5
Cost of Products
Cost of Services
Gross Profit	1.9	-0	-0.1	-0.3	-0.5	-0.6
Gross Profit Margin	30.3%	-0.7%	-2.2%	-8.7%	-12.4%	-13.6%
Selling, General & Administrative Expenses	63.5	49.3	43.5	41.3	40.6	39.9
Selling, General and Administrative
Research & Development Expenses	46.1	45.1	49.3	53.1	54.3	54.5
Research and Development
Other Operating Expenses	—	—	—	40.3	—	—
Impairment of Goodwill
Impairment Loss
Impairment of Other Noncurrent Assets
Operating Profit	-107.7	-94.5	-92.9	-135	-95.4	-95
Operating Margin	-1,706.6%	-2,176.3%	-2,211.2%	-3,440.2%	-2,406.2%	-2,165.2%
Interest and Investment Income	2.4	2.1	1.7	1.4	2.1	2.7
Interest and Dividend Income
Interest Expense	-0.9	-0	-0	-0	-0	-0
Interest Expense
Non-Operating Income	8.5	5.5	5.6	5.6	-3	0.3
Unrealized and Realized Appreciation (Depreciation) in Fair Value of Equity Securities and Preferred Stock, Net
Equity in Net Loss of Affiliates
Equity in Net Income of Affiliates
Other Income, Net
Total Non-Operating Income	9.9	7.6	7.3	7	-0.9	3
Income Before Provision for Income Taxes	-97.7	-86.9	-85.6	-128	-96.2	-92.1
Provision for Income Taxes	—	—	—	-1.8	—	—
Income Tax Benefit
Consolidated Net Income	-97.7	-86.9	-85.6	-126.2	-96.2	-92.1
Net Income Attributable to Minority Interests and Other	—	—	—	—	—	—
Net Loss Attributable to the Noncontrolling Interests
Net Income Attributable to Discontinued Operations	—	—	—	—	—	—
Loss from Discontinued Operations, Net of Income Tax Benefit
Income from Discontinued Operations, Net of Income Tax Benefit
Net Income Attributable to Common Shareholders	-97.7	-86.9	-85.6	-126.2	-96.2	-92.1
Basic EPS	-1.4	-0.4	-0.6	-0.5	-0.6	-0.5
Diluted EPS	-1.4	-0.4	-0.6	-0.5	-0.6	-0.5
Basic Weighted Average Shares Outstanding	295.5	287.7	276.7	267.7	256.6	249.8
Total Shares Outstanding	353.8	297.8	295.1	292.9	292.9	252.7
Diluted Weighted Average Shares Outstanding	295.5	287.7	276.7	267.7	256.6	249.8
EBITDA	-104.9	-91.9	-89.3	-130.5	-89.9	-88.6
Effective Tax Rate	—	—	—	1.4%	—	—